Chargement en cours...

Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs

HER2-positive breast cancer is an aggressive tumour that affects approximately one in five breast cancer women. Clinical studies have shown that HER2-positive cancer have different characteristics from other mammary tumors: a more rapid progression of the disease, an earlier age of onset (women of c...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Clementina Savastano, Fortuna Lombardi
Format: Artigo
Langue:Inglês
Publié: AboutScience Srl 2018-10-01
Collection:AboutOpen
Sujets:
Accès en ligne:https://journals.aboutscience.eu/index.php/aboutopen/article/view/135
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!